{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:30:19Z","timestamp":1794454219148,"version":"4.9.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12432-1","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:03:57Z","timestamp":1721887437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Valuable insights from the epacadostat plus pembrolizumab clinical trials in solid cancers"],"prefix":"10.1186","volume":"23","author":[{"given":"Tara C.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"12432_CR1","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","volume":"23","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, O\u2019Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23:3269\u201376.","journal-title":"Clin Cancer Res"},{"key":"12432_CR2","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell TC, Hamid O, Smith DC, et al. Epacadostat Plus Pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037). J Clin Oncol. 2018;36:3223\u201330.","journal-title":"J Clin Oncol"},{"key":"12432_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/oncolo\/oyac174","volume":"27","author":"JD Powderly","year":"2022","unstructured":"Powderly JD, Klempner SJ, Naing A, et al. Epacadostat plus pembrolizumab and chemotherapy for advanced solid tumors: results from the phase I\/II ECHO-207\/KEYNOTE-723 study. Oncologist. 2022;27:905\u2013e848.","journal-title":"Oncologist"},{"key":"12432_CR4","doi-asserted-by":"crossref","unstructured":"Perez RP, Riese MJ, Lewis KD et al. Epacadostat plus Nivolumab in patients with advanced solid tumors: preliminary phase I\/II results of ECHO-204. J Clin Oncol. 2017;35 Suppl: Abstract 3003.","DOI":"10.1200\/JCO.2017.35.15_suppl.3003"},{"key":"12432_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O, et al. Epacadostat plus Pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20:1083\u201397.","journal-title":"Lancet Oncol"},{"key":"12432_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"12432_CR7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab with Tumor Response and Survival among patients with Advanced Melanoma. JAMA. 2016;315:1600\u20139.","journal-title":"JAMA"},{"key":"12432_CR8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"12432_CR9","first-page":"Abstract28","volume":"8 Suppl 3","author":"M Smith","year":"2020","unstructured":"Smith M, Newton R, Owens S, et al. Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies. J Immunother Cancer. 2020;8 Suppl 3:Abstract28.","journal-title":"J Immunother Cancer"},{"key":"12432_CR10","doi-asserted-by":"publisher","first-page":"1134551","DOI":"10.3389\/fimmu.2023.1134551","volume":"14","author":"E Panfili","year":"2023","unstructured":"Panfili E, Mondanelli G, Orabona C, et al. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1. Front Immunol. 2023;14:1134551.","journal-title":"Front Immunol"},{"key":"12432_CR11","doi-asserted-by":"publisher","first-page":"1346686","DOI":"10.3389\/fimmu.2024.1346686","volume":"15","author":"S Rossini","year":"2024","unstructured":"Rossini S, Ambrosino S, Volpi C, et al. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells. Front Immunol. 2024;15:1346686.","journal-title":"Front Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12432-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12432-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12432-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:05:51Z","timestamp":1721887551000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12432-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":11,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["12432"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12432-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"25 July 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Participation in scientific advisory boards for Merck, BMS, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1269"}}